Surgery Today

, Volume 43, Issue 4, pp 353–360

Management of Barrett’s esophageal carcinoma

  • Tatsuya Miyazaki
  • Takanori Inose
  • Naritaka Tanaka
  • Takehiko Yokobori
  • Shigemasa Suzuki
  • Daigo Ozawa
  • Makoto Sohda
  • Masanobu Nakajima
  • Minoru Fukuchi
  • Hiroyuki Kato
  • Hiroyuki Kuwano
Review Article


Barrett’s esophagus (BE) is the premalignant lesion from which esophageal adenocarcinoma near the esophagogastric junction arises. The management of BE and the treatment of Barrett’s esophageal adenocarcinoma (BEA) are important clinical issues in Europe and the United States. As the Helicobacter pylori infection rate in Japan is decreasing in the younger population, the incidence of BE and adenocarcinoma arising from BE may start increasing. Thus, we review the current status of BEA and its management. Magnifying endoscopy with narrow-band imaging is important for diagnosing dysplasia arising from BE. In Japan, adenocarcinoma arising from BE is managed the same way as squamous cell carcinoma in the same location. Strategies to prevent BEA may include medication such as non-steroidal anti-inflammatory drugs and proton pump inhibitors, and anti-reflux surgery. Understanding the pathophysiology of BE will help to reduce the incidence of BEA.


Barrett’s esophagus GERD Esophageal adenocarcinoma 


  1. 1.
    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Hoshihara Y, Kogure T, Yamamoto T, Hashimoto M, Hoteya O. Endoscopic diagnosis of Barrett’s esophagus. Nihon Rinsho. 2005;63(8):1394–8.PubMedGoogle Scholar
  4. 4.
    Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131(5):1392–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Japan Esophageal Society. Japanese Classification Esophageal Society. 10th ed. Tokyo: Kanehara & Co., Ltd.; 2008.Google Scholar
  6. 6.
    Kinjo T, Kusano C, Oda I, Gotoda T. Prague C&M and Japanese criteria: shades of Barrett’s esophagus endoscopic diagnosis. J Gastroenterol. 2010;45(10):1039–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Barrett NR. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg. 1950;38(150):175–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax. 1953;8(2):87–101.PubMedCrossRefGoogle Scholar
  9. 9.
    Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 1957;41(6):881–94.PubMedGoogle Scholar
  10. 10.
    Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103(3):788–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Takubo K, Nixon JM, Jass JR. Ducts of esophageal glands proper and paneth cells in Barrett’s esophagus: frequency in biopsy specimens. Pathology. 1995;27(4):315–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Takubo K, Vieth M, Aryal G, Honma N, Sawabe M, Arai T, et al. Islands of squamous epithelium and their surrounding mucosa in columnar-lined esophagus: a pathognomonic feature of Barrett’s esophagus? Hum Pathol. 2005;36(3):269–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Spechler SJ. Clinical practice. Barrett’s Esophagus. N Engl J Med. 2002;346(11):836–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119(2):333–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Pohl H, Welch HG. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19(6):1468–70.PubMedCrossRefGoogle Scholar
  17. 17.
    The Japanese Society for Esophageal Disease. Comprehensive Registry for Esophageal Cancer in Japan. 3rd ed; 2002.Google Scholar
  18. 18.
    Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):872–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993–2001. Jpn J Clin Oncol. 2008;38(7):464–8.PubMedCrossRefGoogle Scholar
  20. 20.
    The Japanese Society for Esophageal Disease, Comprehensive Registry of Esophageal Cancer in Japan 1998, r. e., Clinical Result of Patients treated with Endoscopically in 1998; 2002.Google Scholar
  21. 21.
    The Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2001; 2009.Google Scholar
  22. 22.
    The Japanese Society for Esophageal Disease, Comprehensive Registry of Esophageal Cancer in Japan (1988–1994). 1st ed; 2000.Google Scholar
  23. 23.
    The Japanese Society for Esophageal Disease. Comprehensive Registry of Esophageal Cancer in Japan (1995, 1996, 1997). 2nd ed; 2001.Google Scholar
  24. 24.
    The Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2002; 2010.Google Scholar
  25. 25.
    The Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2003; 2011.Google Scholar
  26. 26.
    Kazui T, Wada H, Fujita H. Thoracic and cardiovascular surgery in Japan during 2003: annual report by The Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg. 2005;53(9):517–36.PubMedCrossRefGoogle Scholar
  27. 27.
    Sakata R, Fujii Y, Kuwano H. Thoracic and cardiovascular surgery in Japan during 2008: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2010;58(7):356–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Sakata R, Fujii Y, Kuwano H. Thoracic and cardiovascular surgery in Japan during 2009: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2011;59(9):636–67.PubMedCrossRefGoogle Scholar
  29. 29.
    Ueda Y, Fujii Y, Kuwano H. Thoracic and cardiovascular surgery in Japan during 2007. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2009;57(9):488–513.PubMedCrossRefGoogle Scholar
  30. 30.
    Ueda Y, Fujii Y, Udagawa H. Thoracic and cardiovascular surgery in Japan during 2006: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2008;56(7):365–88.PubMedCrossRefGoogle Scholar
  31. 31.
    Ueda Y, Osada H, Osugi H. Thoracic and cardiovascular surgery in Japan during 2005. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2007;55(9):377–99.PubMedCrossRefGoogle Scholar
  32. 32.
    Kazui T, Osada H, Fujita H. Thoracic and cardiovascular surgery in Japan during 2004. Jpn J Thorac Cardiovasc Surg. 2006;54(8):363–85.PubMedCrossRefGoogle Scholar
  33. 33.
    Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33(4):306–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett’s oesophagus. Aliment Pharmacol Ther. 2007;26(11–12):1465–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol. 1999;94(4):884–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett’s esophagus, Barrett’s dysplasia, and Barrett’s adenocarcinoma. Am J Gastroenterol. 2000;95(2):387–94.PubMedCrossRefGoogle Scholar
  37. 37.
    Lord RV, Frommer DJ, Inder S, Tran D, Ward RL. Prevalence of Helicobacter pylori infection in 160 patients with Barrett’s oesophagus or Barrett’s adenocarcinoma. Aust N Z J Surg. 2000;70(1):26–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer. 1996;67(2):269–74.PubMedCrossRefGoogle Scholar
  39. 39.
    Mutoh H, Hakamata Y, Sato K, Eda A, Yanaka I, Honda S, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun. 2002;294(2):470–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Mutoh H, Sakurai S, Satoh K, Osawa H, Hakamata Y, Takeuchi T, et al. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut. 2004;53(10):1416–23.PubMedCrossRefGoogle Scholar
  41. 41.
    Zagorowicz E, Jankowski J. Molecular changes in the progression of Barrett’s oesophagus. Postgrad Med J. 2007;83(982):529–35.PubMedCrossRefGoogle Scholar
  42. 42.
    Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett’s esophagus surveillance. Clin Cancer Res. 2007;13(2 Pt 1):659–65.PubMedCrossRefGoogle Scholar
  43. 43.
    Coppola D, Schreiber RH, Mora L, Dalton W, Karl RC. Significance of Fas and retinoblastoma protein expression during the progression of Barrett’s metaplasia to adenocarcinoma. Ann Surg Oncol. 1999;6(3):298–304.PubMedCrossRefGoogle Scholar
  44. 44.
    Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL, et al. p16 mutation spectrum in the premalignant condition Barrett’s esophagus. PLoS ONE. 2008;3(11):e3809.PubMedCrossRefGoogle Scholar
  45. 45.
    Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett’s metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology. 1993;105(6):1637–42.PubMedGoogle Scholar
  46. 46.
    Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case-control study. Am J Gastroenterol. 2009;104(11):2673–80.PubMedCrossRefGoogle Scholar
  47. 47.
    O’Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100(6):1257–64.PubMedCrossRefGoogle Scholar
  48. 48.
    Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001;96(4):990–6.PubMedGoogle Scholar
  49. 49.
    Osterheld MC, Bian YS, Bosman FT, Benhattar J, Fontolliet C. Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol. 2002;117(3):451–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, et al. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett’s esophagus and esophageal adenocarcinomas. Mod Pathol. 1998;11(9):805–13.PubMedGoogle Scholar
  51. 51.
    Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95(7):1669–76.PubMedGoogle Scholar
  52. 52.
    Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett’s esophagus, ulcerative colitis, and Crohn’s disease. Am J Surg Pathol. 2006;30(7):871–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Moyes LH, Going JJ. Still waiting for predictive biomarkers in Barrett’s oesophagus. J Clin Pathol. 2011;64(9):742–50.PubMedCrossRefGoogle Scholar
  54. 54.
    Meyer W, Vollmar F, Bar W. Barrett-esophagus following total gastrectomy. A contribution to it’s pathogenesis. Endoscopy. 1979;11(2):121–6.Google Scholar
  55. 55.
    Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Gastric surgery is not a risk for Barrett’s esophagus or esophageal adenocarcinoma. Gastroenterology. 2001;121(6):1281–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Akiyama T, Inamori M, Akimoto K, Iida H, Endo H, Hosono K, et al. Gastric surgery is not a risk factor for erosive esophagitis or Barrett’s esophagus. Scand J Gastroenterol. 2010;45(4):403–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N Engl J Med. 1976;295(9):476–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc. 2000;52(2):197–203.PubMedCrossRefGoogle Scholar
  59. 59.
    Gross CP, Canto MI, Hixson J, Powe NR. Management of Barrett’s esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol. 1999;94(12):3440–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2000;51(5):560–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Horwhat JD, Maydonovitch CL, Ramos F, Colina R, Gaertner E, Lee H, et al. A randomized comparison of methylene blue-directed biopsy versus conventional four-quadrant biopsy for the detection of intestinal metaplasia and dysplasia in patients with long-segment Barrett’s esophagus. Am J Gastroenterol. 2008;103(3):546–54.PubMedCrossRefGoogle Scholar
  62. 62.
    Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s oesophagus. Gut. 2003;52(1):24–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Yuki T, Amano Y, Kushiyama Y, Takahashi Y, Ose T, Moriyama I, et al. Evaluation of modified crystal violet chromoendoscopy procedure using new mucosal pit pattern classification for detection of Barrett’s dysplastic lesions. Dig Liver Dis. 2006;38(5):296–300.PubMedCrossRefGoogle Scholar
  64. 64.
    Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett’s esophagus. Gastrointest Endosc. 2001;53(6):559–65.PubMedCrossRefGoogle Scholar
  65. 65.
    Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127(1):310–30.PubMedCrossRefGoogle Scholar
  66. 66.
    Hirota WK, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63(4):570–80.PubMedCrossRefGoogle Scholar
  67. 67.
    Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut. 2006;55(4):442.PubMedCrossRefGoogle Scholar
  68. 68.
    Asaoka D, Nagahara A, Oguro M, Kurosawa A, Osada T, Kawabe M, et al. Utility of autofluorescence imaging video endoscopy in screening for Barrett’s esophagus. Endoscopy. 2009;41(Suppl 2):E113.PubMedCrossRefGoogle Scholar
  69. 69.
    Kara MA, Bergman JJ. Autofluorescence imaging and narrow-band imaging for the detection of early neoplasia in patients with Barrett’s esophagus. Endoscopy. 2006;38(6):627–31.PubMedCrossRefGoogle Scholar
  70. 70.
    Curvers WL, Singh R, Song LM, Wolfsen HC, Ragunath K, Wang K, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett’s oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut. 2008;57(2):167–72.PubMedCrossRefGoogle Scholar
  71. 71.
    Jobe BA, Hunter JG, Chang EY, Kim CY, Eisen GM, Robinson JD, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett’s esophagus: a randomized and blinded comparison. Am J Gastroenterol. 2006;101(12):2693–703.PubMedCrossRefGoogle Scholar
  72. 72.
    Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett’s esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5(3):312–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Kadri SR, Lao-Sirieix P, O’Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.PubMedCrossRefGoogle Scholar
  74. 74.
    Mannath J, Subramanian V, Hawkey CJ, Ragunath K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis. Endoscopy. 2010;42(5):351–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Singh R, Anagnostopoulos GK, Yao K, Karageorgiou H, Fortun PJ, Shonde A, et al. Narrow-band imaging with magnification in Barrett’s esophagus: validation of a simplified grading system of mucosal morphology patterns against histology. Endoscopy. 2008;40(6):457–63.PubMedCrossRefGoogle Scholar
  76. 76.
    Sharma P, Hawes RH, Bansal A, Gupta N, Curvers W, Rastogi A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut; 2012.Google Scholar
  77. 77.
    Bollschweiler E, Baldus SE, Schroder W, Prenzel K, Gutschow C, Schneider PM, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy. 2006;38(2):149–56.PubMedCrossRefGoogle Scholar
  78. 78.
    Gockel I, Domeyer M, Sgourakis GG, Schimanski CC, Moehler M, Kirkpatrick CJ, et al. Prediction model of lymph node metastasis in superficial esophageal adenocarcinoma and squamous cell cancer including D2–40 immunostaining. J Surg Oncol. 2009;100(3):191–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Seewald S, Ang TL, Soehendra N. Endoscopic mucosal resection of Barrett’s oesophagus containing dysplasia or intramucosal cancer. Postgrad Med J. 2007;83(980):367–72.PubMedCrossRefGoogle Scholar
  80. 80.
    Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57(9):1200–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Ikeda K, Isomoto H, Oda H, Shikuwa S, Mizuta Y, Iwasaki K, et al. Endoscopic submucosal dissection of a minute intramucosal adenocarcinoma in Barrett’s esophagus. Dig Endosc. 2009;21(1):34–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Van Laethem JL, Jagodzinski R, Peny MO, Cremer M, Deviere J. Argon plasma coagulation in the treatment of Barrett’s high-grade dysplasia and in situ adenocarcinoma. Endoscopy. 2001;33(3):257–61.PubMedCrossRefGoogle Scholar
  83. 83.
    Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett’s dysplasia or cancer. Aliment Pharmacol Ther. 2004;20(10):1125–31.PubMedCrossRefGoogle Scholar
  84. 84.
    Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Laser and multipolar electrocoagulation ablation of early Barrett’s adenocarcinoma: long-term follow-up. Gastrointest Endosc. 1999;49(4 Pt 1):442–6.PubMedCrossRefGoogle Scholar
  85. 85.
    van de Ven C, De Leyn P, Coosemans W, Van Raemdonck D, Lerut T. Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction. Eur J Cardiothorac Surg. 1999;15(6):769–73.PubMedCrossRefGoogle Scholar
  86. 86.
    Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236(2):177–83.PubMedCrossRefGoogle Scholar
  87. 87.
    Gockel I, Sgourakis G, Lyros O, Polotzek U, Schimanski CC, Lang H, et al. Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol. 2011;5(3):371–84.PubMedCrossRefGoogle Scholar
  88. 88.
    Ancona E, Rampado S, Cassaro M, Battaglia G, Ruol A, Castoro C, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15(11):3278–88.PubMedCrossRefGoogle Scholar
  89. 89.
    Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007; 246(6):992–1000; discussion 1000–1.Google Scholar
  91. 91.
    Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.PubMedCrossRefGoogle Scholar
  92. 92.
    Network®, N.C.C., NCCN Clinical Practice Guidelines in Oncology™ Esophageal Cancer V.2.2010; 2010.Google Scholar
  93. 93.
    Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Lerut T, Coosemans W, van Raemdonck D, Dillemans B, De Leyn P, Marnette JM, et al. Surgical treatment of Barrett’s carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg. 1994; 107(4):1059–65; discussion 1065–6.Google Scholar
  95. 95.
    Peracchia A, Bonavina L, Via A, Incarbone R. Current trends in the surgical treatment of esophageal and cardia adenocarcinoma. J Exp Clin Cancer Res. 1999;18(3):289–94.PubMedGoogle Scholar
  96. 96.
    Mariette C, Finzi L, Piessen G, Van Seuningen I, Triboulet JP. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg. 2005;29(1):39–45.PubMedCrossRefGoogle Scholar
  97. 97.
    Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253(4):689–98.PubMedCrossRefGoogle Scholar
  98. 98.
    Zingg U, Montani M, Busch M, Metzger U, Went P, Oertli D. Prognostic influence of immunohistochemically detected lymph node micrometastasis and histological subtype in pN0 oesophageal cancer. Eur J Surg Oncol. 2009;35(6):593–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124(1):47–56.PubMedCrossRefGoogle Scholar
  100. 100.
    El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99(10):1877–83.PubMedCrossRefGoogle Scholar
  101. 101.
    Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett’s oesophagus. Aliment Pharmacol Ther. 2008;27(4):321–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, DeMeester SR, Crookes PF, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2001;234(4):532–8; discussion 538–9.Google Scholar
  103. 103.
    O’Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV. Long-term clinical and pathologic response of Barrett’s esophagus after antireflux surgery. Am J Surg. 2004;188(1):27–33.PubMedCrossRefGoogle Scholar
  104. 104.
    Monahan KJ, Youd PL, Willson P. Esophageal adenocarcinoma after Nissen’s fundoplication for Barrett’s esophagus: report of a case. Surg Today. 2010;40(12):1173–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Tatsuya Miyazaki
    • 1
  • Takanori Inose
    • 1
  • Naritaka Tanaka
    • 1
  • Takehiko Yokobori
    • 1
  • Shigemasa Suzuki
    • 1
  • Daigo Ozawa
    • 1
  • Makoto Sohda
    • 1
  • Masanobu Nakajima
    • 2
  • Minoru Fukuchi
    • 1
  • Hiroyuki Kato
    • 2
  • Hiroyuki Kuwano
    • 1
  1. 1.Department of General Surgical ScienceGunma University Graduate SchoolMaebashiJapan
  2. 2.First Department of SurgeryDokkyo Medical UniversityTochigiJapan

Personalised recommendations